Influence
March 21, 2022

Revolutionizing research through pragmatic trials

Revolutionizing research through pragmatic trials

Regenstrief Institute Research Scientist Kathleen Unroe, M.D., MHA, M.S., is at the forefront of the next generation of research methodology: pragmatic trials. Pragmatic trials are designed to evaluate the effectiveness of interventions in real-life practice, speeding up the time from discovery to implementation.  

Dr. Unroe, along with Regenstrief faculty member Susan Hickman, PhD, is leading one of few pragmatic trials funded by the National Institute on Aging. The APPROACHES (Aligning Patient Preferences – a Role Offering Alzheimer’s patients, Caregivers, and Healthcare providers Education and Support) trial is being conducted in 150 nursing homes, testing an intervention to support advance care planning.  

She is also part of the IMPACT Collaboratory, a research incubator to develop pragmatic trials and train researchers to design and execute them.  

In 2021, Dr. Unroe spoke at a conference about pragmatic trials in long-term care facilities. The event identified priorities and best practices for trials taking place in these real-world settings. 

Dr. Unroe says she is excited about the potential of pragmatic trials for creating solutions as well as creating partnerships between researchers and healthcare systems.  

In addition to being a research scientist in the IU Center for Aging Research at Regenstrief Institute, Dr. Unroe is an associate professor at the IU School of Medicine and a practicing geriatrician. 

  • Kathleen Unroe

Related News

Johanne Eliacin and Sophia Wang

Factors influencing participation of Black and White Americans in Alzheimer’s disease biomarker research

Regenstrief researcher leads study of barriers to participation and drivers of engagement The use of Alzheimer’s disease (AD) biomarkers

Multi-state study reports COVID-19 mRNA vaccines protective during Omicron BA.4/BA.5 predominance

Multi-state study reports COVID-19 mRNA vaccines protective during Omicron BA.4/BA.5 predominance

Study also finds less severe disease during BA.4/BA.5 predominance compared to earlier Omicron variants A multi-state study from the

Dr. Kurt Kroenke at the 2023 Indianapolis Business Journal's Health Care Heroes Awards Breakfast

IBJ Honors Regenstrief research scientist with Heath Care Hero Award 

The Indianapolis Business Journal (IBJ) honored Regenstrief Research Scientist Kurt Kroenke, M.D., MACP, as a Health Care Hero at

LOINC Logo

LOINC 2.74 Release Webinar scheduled for spring 2023

LOINC® from Regenstrief Institute will host an educational webinar for the February 2023 2.74 release of new concepts, scheduled